Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors

Document first published:
Page updated:
Topic:
Publication type:

NHS England will commission emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages) in accordance with the criteria outlined in this policy.

Document

Clinical commissioning policy: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

Clinical commissioning policy: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

  • PDF
  • 256 KB

Document

Clinical panel report: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

Clinical panel report: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

  • PDF
  • 126 KB

Document

Equality and health inequalities impact assessment: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

Equality and health inequalities impact assessment: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

  • PDF
  • 202 KB

Document

CPAG summary report: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

CPAG summary report: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

  • PDF
  • 316 KB

Document

Evidence review: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

Evidence review: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

  • PDF
  • 521 KB

Document

Stakeholder engagement report: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

Stakeholder engagement report: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)

  • PDF
  • 190 KB